Vernalis announces positive results for Parkinson's Disease treatment study

AIM-listed pharmaceutical company Vernalis has published positive results for a Receptor Occupancy study of an antagonist with potential applications for Parkinson's disease and other Central Nervous System indications.

AIM-listed pharmaceutical company Vernalis has published positive results for a Receptor Occupancy study of an antagonist with potential applications for Parkinson's disease and other Central Nervous System indications.

The study examined the relationship between dose, plasma concentration and blockade of the so-called "A2A" receptor using positron emission tomography scanning and included a preliminary evaluation, using functional magnetic resonance imaging of the effects of V81444, the particular antangonist, on cognitive function.

The study demonstrated that full A2A blockade could be achieved with single doses that were within the range of doses previously shown to be well tolerated with no safety concerns.

As such, the study has provided confirmation of the appropriate dose to be used in the forthcoming clinical proof-of-concept trial.

Vernalis now plans to initiate, in the first half of next year, a Phase IIa proof-of-concept study to further evaluate the pharmacokinetics, safety and tolerability of V81444 in patients, together with an evaluation of efficacy in a target patient population.

Ian Garland, Chief Executive Officer of Vernalis, commented: "We are very pleased with these results and are already actively preparing for the continued development of this exciting programme over the next 12 months".

Vernalis's share price was up 0.55% to 23p at 09:27 on Wednesday morning.

MF

Recommended

The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
23 Jan 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023
Investing trends to watch out for in 2023: what analysts say
Investment strategy

Investing trends to watch out for in 2023: what analysts say

What are sensible strategies for high inflationary times? We ask analysts to find out.
22 Dec 2022

Most Popular

Best savings accounts – February 2023
Savings

Best savings accounts – February 2023

Interest rates on cash savings are making a comeback. We look at the best savings accounts on the market now
3 Feb 2023
The best one-year fixed savings accounts - February 2023
Savings

The best one-year fixed savings accounts - February 2023

Earn almost 5% on one-year fixed savings accounts.
3 Feb 2023
After slumping 42% last year, what's next for Scottish Mortgage?
Investment trusts

After slumping 42% last year, what's next for Scottish Mortgage?

After a spectacular couple of decades, the Scottish Mortgage Investment Trust fell by 42% last year. We take a look at the trust's performance and dis…
3 Feb 2023